Literature DB >> 2912361

Low-density lipoprotein (LDL) distribution shown by 99mtechnetium-LDL imaging in patients with myeloproliferative diseases.

S Vallabhajosula1, H S Gilbert, S J Goldsmith, M Paidi, M M Hanna, H N Ginsberg.   

Abstract

STUDY
OBJECTIVE: To image and identify by noninvasive methods the sites of low-density lipoprotein (LDL) catabolism in patients with myeloproliferative disease in whom chronic hypocholesterolemia was previously reported. STUDY
DESIGN: The 99mTechnetium-LDL (Tc-LDL) distribution in patients with myeloproliferative diseases was compared with that in normal subjects. The Tc-LDL distribution was also compared with the distribution and organ uptake of a macrophage-seeking radiotracer. 99mTc-sulfur colloid (Tc-SC).
SETTING: Major metropolitan referral center and institutional practice. PATIENTS: Three normal subjects, two patients with polycythemia vera, two with post polycythemia myeloid metaplasia, and one with agnogenic myeloid metaplasia. The patients were being managed with hydroxyurea or phlebotomy. INTERVENTION: Ten mCi of Tc-LDL (homologous) was injected intravenously.
MEASUREMENTS AND MAIN RESULTS: Gamma camera images of Tc-LDL biodistribution and organ uptake were obtained 4 hours after injection of the tracer. In normal subjects, the Tc-LDL was predominantly taken up by the liver, with relative nonvisualization of spleen and central or peripheral marrow. Patients with myeloproliferative disease showed marked splenic uptake of Tc-LDL. Peripheral bone marrow uptake extended to the lower tibia in two patients with post-polycythemia myeloid metaplasia. Splenic and bone marrow uptake paralleled that of Tc-SC. Hypercellularity of central and peripheral marrow at the sites of Tc-LDL uptake was confirmed by biopsy specimens. The Tc-LDL uptake, however, was not correlated with collagen fibrosis.
CONCLUSIONS: These results indicate that spleen and bone marrow are sites of LDL catabolism in patients with myeloproliferative disease and suggest the role of macrophages in the hypocholesterolemia and accelerated LDL catabolism of myeloproliferative disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912361     DOI: 10.7326/0003-4819-110-3-208

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

1.  Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.

Authors:  Ayalew Tefferi; Maura Nicolosi; Domenico Penna; Mythri Mudireddy; Natasha Szuber; Terra L Lasho; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh D Pardanani
Journal:  Blood Adv       Date:  2018-08-14

2.  Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug.

Authors:  D Filipowska; T Filipowski; B Morelowska; W Kazanowska; T Laudanski; S Lapinjoki; M Akerlund; A Breeze
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.

Authors:  S Vitols; B Angelin; S Ericsson; G Gahrton; G Juliusson; M Masquelier; C Paul; C Peterson; M Rudling; K Söderberg-Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

Authors:  Stefanie Slot; Niels W C J van de Donk; René H J Otten; Bouke J H Boden; Josée Zijlstra; Pieter G H M Raijmakers; Sonja Zweegman
Journal:  Cancer Imaging       Date:  2021-04-20       Impact factor: 3.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.